Osmotic stimulation of vasopressin acutely impairs glucose regulation: A counterbalanced, crossover trial

American Journal of Clinical Nutrition

Volumn 110, Issue 6, 2019, Pages 1344-1352

  Jansen, Lisa T ^a   Suh, Hyungyu ^b   Adams, J D ^c   Sprong, Cameron A ^a   Seal, Adam D ^a,b   Scott, Dylan M ^a   Butts, Cory L ^d   Melander, Olle ^e   Kirkland, Tracie W ^a   Vanhaecke, Tiphaine ^f   Dolci, Alberto ^f   Lemetais, Guillaume ^f   Perrier, Erica T ^f   Kavouras, Stavros A ^b  

^a UNIVERSITY OF ARKANSAS   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d WEBER STATE UNIVERSITY   (United States)

^e LUND UNIVERSITY   (Sweden)

^f Danone Research   (France)

Author keywords

cellular dehydration; copeptin; dehydration; diabetes; glucagon; hydration; hyperosmolality; hypohydration; oral glucose tolerance test; underhydration

Indexed keywords

COPEPTIN; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; GLYCOPEPTIDE; SODIUM CHLORIDE; VASOPRESSIN DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE MARKER; FEMALE; FLUID INTAKE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MENSTRUAL CYCLE; ORAL GLUCOSE TOLERANCE TEST; OSMOSIS; PLASMA OSMOLALITY; PLASMA VOLUME; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE BLIND PROCEDURE; URINE SAMPLING; BLOOD; CHEMISTRY; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; OSMOLARITY; PLASMA; RANDOMIZED CONTROLLED TRIAL;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; FEMALE; GLUCAGON; GLUCOSE TOLERANCE TEST; GLYCOPEPTIDES; HUMANS; INSULIN; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; OSMOSIS; PLASMA; SODIUM CHLORIDE; VASOPRESSINS;

EID: 85075421755     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.1093/ajcn/nqz236     Document Type: Article

References (57)

1. International Diabetes Federation. IDF annual report 2017 [Internet]. [cited February 14, 2019]. Available from: https://www.idf.org/ our-activities/advocacy-awareness/resources-and-tools/149:idf-annualreport-2017.html.
2. WHO. Global report on diabetes [Internet].WHO, 2016 [cited February 14, 2019]. Available from: https://apps.who.int/iris/bitstream/handle/1 0665/204871/9789241565257eng.pdf;jsessionid=B97410767D0E9B 0E93DD20C4D8872E83?sequence=1.
3. Enhorning S, Bankir L, Bouby N, Struck J, Hedblad B, Persson M, Morgenthaler NG, Nilsson PM, Melander O. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond) 2013;37(4):598-603.
4. Enhorning S, Struck J, Wirfalt E, Hedblad B, Morgenthaler NG, Melander O. Plasma copeptin, a unifying factor behind the metabolic syndrome. J Clin Endocrinol Metab 2011;96(7):E1065-72.
5. Abbasi A, Corpeleijn E, Meijer E, Postmus D, Gansevoort RT, Gans RO, Struck J, Hillege HL, Stolk RP, Navis G, et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 2012;55(7):1963-70.
6. Roussel R, Fezeu L, Bouby N, Balkau B, Lantieri O, Alhenc-Gelas F, Marre M, Bankir L, Group DESIRS. Low water intake and risk for newonset hyperglycemia. Diabetes Care 2011;34(12):2551-4.
7. Taveau C, Chollet C, Bichet DG, Velho G, Guillon G, Corbani M, Roussel R, Bankir L, Melander O, Bouby N. Acute and chronic hyperglycemic effects of vasopressin in normal rats: involvement of V1A receptors. Am J Physiol Endocrinol Metab 2017;312(3):E127-E35.
8. Taveau C, Chollet C, Waeckel L, Desposito D, Bichet DG, Arthus MF, Magnan C, Philippe E, Paradis V, Foufelle F, et al. Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia 2015;58(5): 1081-90.
9. Fujiwara Y, Hiroyama M, Sanbe A, Yamauchi J, Tsujimoto G, Tanoue A. Mutual regulation of vasopressin-and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice. J Endocrinol 2007;192(2):361-9.
10. Heida JE, Boesten LSM, Ettema EM, Muller Kobold AC, Franssen CFM, Gansevoort RT, Zittema D. Comparison of ex vivo stability of copeptin and vasopressin. Clin Chem Lab Med 2017;55(7): 984-92.
11. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52(1):112-9.
12. Enhorning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, Struck J, Morgenthaler NG, Bergmann A, Lindholm E, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010;121(19):2102-8.
13. Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N. Copeptin, insulin resistance, and risk of incident diabetes in older men. J Clin Endocrinol Metab 2015;100(9): 3332-9.
14. Thornton SN. Thirst and hydration: physiology and consequences of dysfunction. Physiol Behav 2010;100(1):15-21.
15. SawkaMN, Cheuvront SN, Carter R 3rd. Human water needs. Nutr Rev 2005;63(6 Pt 2):S30-9.
16. Cheuvront SN, Ely BR, Kenefick RW, SawkaMN. Biological variation and diagnostic accuracy of dehydration assessment markers. Am J Clin Nutr 2010;92(3):565-73.
17. Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T, Watanabe H, Miyashita Y, Shirai K. Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism 2009;58(5):708-13.
18. Thornton SN. Angiotensin inhibition and longevity: a question of hydration. Pflugers Arch 2011;461(3):317-24.
19. Rizza RA,Mandarino LJ,Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab 1982;54(1):131-8.
20. Stachenfeld NS, Splenser AE, Calzone WL, TaylorMP, Keefe DL. Sex differences in osmotic regulation of AVP and renal sodium handling. J Appl Physiol (1985) 2001;91(4):1893-901.
21. Feig PU, McCurdy DK. The hypertonic state. N Engl J Med 1977;297(26):1444-54.
22. Bratusch-Marrain PR, DeFronzo RA. Impairment of insulinmediated glucose metabolism by hyperosmolality in man. Diabetes 1983;32(11):1028-34.
23. Stachenfeld NS, Keefe DL. Estrogen effects on osmotic regulation of AVP and fluid balance. Am J Physiol Endocrinol Metab 2002;283(4):E711-21.
24. Kaneko T, Wang PY, Tawata M, Sato A. Low carbohydrate intake before oral glucose-tolerance tests. Lancet 1998;352(9124): 289.
25. Panel on Dietary Reference Intakes for Electrolytes andWater, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board. 2004 dietary reference intakes for water, potassium, sodium, chloride, and sulfate. Washington DC: National Academy Press; 2004.
26. Drewnowski A, Rehm CD, Constant F. Water and beverage consumption among adults in the United States: cross-sectional study using data from NHANES 2005-2010. BMC Public Health 2013;13(1):1068.
27. Hagan RD, Diaz FJ, Horvath SM. Plasma volume changes with movement to supine and standing positions. J Appl Physiol 1978;45(3):414-7.
28. Robinson TE, Sue DY, Huszczuk A,Weiler-Ravell D, Hansen JE. Intraarterial and cuff blood pressure responses during incremental cycle ergometry. Med Sci Sports Exerc 1988;20(2):142-9.
29. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994;23(3):395-401.
30. Dill DB, Costill DL. Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. J Appl Physiol 1974;37(2):247-8.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-9.
32. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22(9):1462-70.
33. Brouns F, Bjorck I, Frayn KN, Gibbs AL, Lang V, Slama G, Wolever TM. Glycaemic index methodology. Nutr Res Rev 2005;18(1): 145-71.
34. Wolever TM. Effect of blood sampling schedule and method of calculating the area under the curve on validity and precision of glycaemic index values. Br J Nutr 2004;91(2):295-301.
35. Spruce BA, McCulloch AJ, Burd J, Orskov H, Heaton A, Baylis PH, Alberti KG. The effect of vasopressin infusion on glucose metabolism in man. Clin Endocrinol (Oxf) 1985;22(4):463-8.
36. Keller U, Szinnai G, Bliz S, Berneis K. Effect of changes in hydration on protein, glucose and lipid metabolism in man: impact on health. Eur J Clin Nutr 2003;57(Suppl 2):S69-S74.
37. Carroll HA, Templeman I, Chen YC, Edinburgh RM, Burch EK, Jewitt JT, Povey G, Robinson TD, Dooley WL, Jones R, et al. The effect of acute hypohydration on glycemic regulation in healthy adults: a randomized crossover trial. J Appl Physiol (1985) 2019;126(2): 422-30.
38. Dumke CL, Slivka DR, Cuddy JS, Hailes WS, Rose SM, Ruby BC. The effect of environmental temperature on glucose and insulin after an oral glucose tolerance test in healthy young men. Wilderness Environ Med 2015;26(3):335-42.
39. Cooper SA, Whaley-Connell A, Habibi J,Wei Y, Lastra G,Manrique C, Stas S, Sowers JR. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol 2007;293(4):H2009-23.
40. Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006;22(6):423-36.
41. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, Melis A, Cavarape A, Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin EndocrinolMetab 2006;91(9):3457-63.
42. Nakamura K, Aoyagi T, Hiroyama M, Kusakawa S, Mizutani R, Sanbe A, Yamauchi J, Kamohara M, Momose K, Tanoue A. Both V(1A) and V(1B) vasopressin receptors deficiency result in impaired glucose tolerance. Eur J Pharmacol 2009;613(1-3):182-8.
43. Hiroyama M, Fujiwara Y, Nakamura K, Aoyagi T, Mizutani R, Sanbe A, Tasaki R, Tanoue A. Altered lipid metabolism in vasopressin V1B receptor-deficient mice. Eur J Pharmacol 2009;602(2-3):455-61.
44. Koshimizu TA, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev 2012;92(4):1813-64.
45. Johnson EC, Bardis CN, Jansen LT, Adams JD, Kirkland TW, Kavouras SA. Reduced water intake deteriorates glucose regulation in patients with type 2 diabetes. Nutr Res 2017;43:25-32.
46. Mazzocchi G, Malendowicz LK, Rebuffat P, Tortorella C, Nussdorfer GG. Arginine-vasopressin stimulates CRH and ACTH release by rat adrenalmedulla, acting via the V1 receptor subtype and a protein kinase C-dependent pathway. Peptides 1997;18(2):191-5.
47. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol 2009;5(7):374-81.
48. Carroll HA, Davis MG, Papadaki A. Higher plain water intake is associated with lower type 2 diabetes risk: a cross-sectional study in humans. Nutr Res 2015;35(10):865-72.
49. Carroll HA, Betts JA, Johnson L. An investigation into the relationship between plain water intake and glycated Hb (HbA1c): a sexstratified, cross-sectional analysis of the UK National Diet and Nutrition Survey (2008-2012). Br J Nutr [Internet] 2016;116:1170-80. doi:10.1017/S0007114516003688.
50. Enhorning S, Tasevska I, Roussel R, Bouby N, Persson M, Burri P, Bankir L, Melander O. Effects of hydration on plasma copeptin, glycemia and gluco-regulatory hormones: a water intervention in humans. Eur J Nutr 2019;58(1):315-24.
51. Lemetais G, Melander O, Vecchio M, Bottin JH, Enhorning S, Perrier ET. Effect of increased water intake on plasma copeptin in healthy adults. Eur J Nutr 2018;57(5):1883-90.
52. Johnson EC, Munoz CX, Jimenez L, Le Bellego L, Kupchak BR, Kraemer WJ, CasaDJ, Maresh CM,Armstrong LE. Hormonal and thirst modulated maintenance of fluid balance in young women with different levels of habitual fluid consumption. Nutrients 2016;8(5):E302.
53. Lundegaard Asferg C, Bjorn Andersen U, Linneberg A, Goetze JP, Holst JJ, Jeppesen JL. Copeptin, a surrogate marker for arginine vasopressin secretion, is positively associated with glucagon. Diabet Med [Internet] 2018. doi:10.1111/dme.13820.
54. Cryer PE. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 2012;153(3): 1039-48.
55. Reaven GM, Chen YD, Golay A, Swislocki AL, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1987;64(1):106-10.
56. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85(11):4053-9.
57. Ahren B. Beta-and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diabetes 2009;58(3): 726-31.